ArticleCancers2020
The
Registry-linked trialAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01221168 (ProGene), which is not on this map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Who cites it
14 citing papers in PubMed.
- Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study.Familial cancer · 2025Article
- Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies.Journal of personalized medicine · 2025Review
- CHEK2-related breast cancer: real-world challenges.Familial cancer · 2025Article
- BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability.Journal of biomedical science · 2024Article
- Association between missense variants of uncertain significance in theFrontiers in genetics · 2023Article
- Article
- Comprehensive Clinical and Genetic Analysis ofGenes · 2022Article
- Article
- Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.JCO global oncology · 2022Article
- Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.Scientific reports · 2022Article
- Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-Than-Expected Prevalence of Recurrent Germline Pathogenic Variants.Frontiers in oncology · 2022Article
- Homologous Recombination Deficiencies and Hereditary Tumors.International journal of molecular sciences · 2021Review
- Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants inCancers · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors.
Andreia BrandãoCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.ORCID 0000-0003-0938-1543
Paula PauloCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Sofia MaiaCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Manuela PinheiroCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Ana PeixotoDepartment of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Marta CardosoCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Maria P SilvaCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Catarina SantosDepartment of Genetics, Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.
Rosalind A EelesThe Institute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-3698-6241
Zsofia Kote-JaraiThe Institute of Cancer Research, London SM2 5NG, UK.
Kenneth MuirDivision of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester M13 9PL, UK.ORCID 0000-0001-6429-988X
Ukgpcs CollaboratorsThe Institute of Cancer Research, London SW7 3RP, UK.
Johanna SchleutkerInstitute of Biomedicine, University of Turku, FI-20014 Turun Yliopisto, 20050 Turku, Finland.ORCID 0000-0002-1863-0305
Ying WangDepartment of Population Science, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA.ORCID 0000-0002-1241-6252
Nora PashayanDepartment of Applied Health Research, University College London, London WC1E 7HB, UK.ORCID 0000-0003-0843-2468
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Apcb BioResourceAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden.
David E NealNuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK.
Børge G NordestgaardFaculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.ORCID 0000-0002-1954-7220
Catherine M TangenSWOG Statistical Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-C102, Seattle, WA 98109-1024, USA.
Melissa C SoutheyPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia.
Alicja WolkUnit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, ML 20892, USA.
Christopher A HaimanCenter for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, DC 98109-1024, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Catharine M L WestDivision of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester M13 9PL, UK.
Sune F NielsenFaculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
Adam S KibelDivision of Urologic Surgery, Brigham and Womens Hospital, 75 Francis Street, Boston, MA 02115, USA.
Olivier CussenotSorbonne Universite, GRC n 5, AP-HP, Tenon Hospital, 4 rue de la Chine, F-75020 Paris, France.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, ML 20892, USA.
Stella KoutrosDivision of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, ML 20892, USA.
Karina Dalsgaard SørensenDepartment of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark.ORCID 0000-0002-4902-5490
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland.ORCID 0000-0002-2819-3057
Eli Marie GrindedalDepartment of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.ORCID 0000-0002-6384-6447
Sue A InglesDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA.
Christiane MaierHumangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany.
Robert J HamiltonDepartment of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Barry S RosensteinDepartment of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
Ana VegaFundación Pública Galega Medicina Xenómica, 15706 Santiago de Compostela, Spain.
The Impact Study Steering Committee And CollaboratorsThe Institute of Cancer Research, London SW7 3RP, UK.
Manolis KogevinasISGlobal, 08036 Barcelona, Spain.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-4623-0544
Kathryn L PenneyChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02184, USA.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-6129-1572
Esther M JohnDepartments of Epidemiology & Population Health and of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304, USA.
Radka KanevaMolecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Susan L NeuhausenDepartment of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA.
Kim De RuyckFaculty of Medicine and Health Sciences, Basic Medical Sciences, Ghent University, Proeftuinstraat 86, 9000 Gent, Belgium.
Azad RazackDepartment of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Lisa F NewcombDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, DC 98109-1024, USA.
Canary Pass InvestigatorsDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, DC 98109-1024, USA.
Davor LesselInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0003-4496-244X
Nawaid UsmaniDepartment of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada.
Frank ClaessensMolecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Campus Gasthuisberg, University of Leuven, Herestraat 49, P.O. Box 901, 3000 Leuven, Belgium.
Manuela Gago-DominguezGroup of Genomic Medicine, Galician Public Foundation of Genomic Medicine, Health Research Institute of Santiago de Compostela (IDIS), Galician Healthcare Service (SERGAS) University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0001-6713-4351
Paul A TownsendDivision of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, Health Innovation Manchester, University of Manchester, Manchester M13 9PL, UK.
Monique J RoobolDepartment of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands.ORCID 0000-0001-6967-1708
The Profile Study Steering CommitteeInstitute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.
The Practical Consortium
Manuel R TeixeiraCancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal.ORCID 0000-0002-4896-5982
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MSWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MSWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6MCancer Research UK 21332Cancer Research UK 29017Cancer Research UK A8197/A16565Cancer Research UK C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135NCI NIH HHS P30 CA016672NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NIH HHS NCI U01 CA188392NIH HHS U19 CA 148537, X01HG007492
Abstract
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the
Indexed as
cancer predispositionCHEK2founder variantprostate cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT01221168ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.